Comparison of fluorine-18 fluorodeoxyglucose positron emission tomography and technetium-99m methoxyisobutylisonitrile scintimammography in the detection of breast tumours

European Journal of Nuclear Medicine

Volumn 24, Issue 9, 1997, Pages 1138-1145

  Palmedo, H ^a   Bender, H ^a   Grunwald F ^a   Mallmann, R ^a   Zamora, P ^a   Krebs, D ^a   Biersack, H J ^a  

^a UNIVERSITY OF BONN   (Germany)

Author keywords

Breast cancer; Fluorine 18 fluorodeoxyglucose; Positron emission tomography; Scintimammography; Technetium 99m methoxyisobutylisonitrile

Indexed keywords

FLUORINE 18; FLUORODEOXYGLUCOSE; METHOXY ISOBUTYL ISONITRILE TECHNETIUM TC 99M;

ADULT; AGED; ARTICLE; AXILLA; BREAST CANCER; BREAST DISEASE; BREAST FIBROADENOMA; CANCER SCINTISCANNING; CANCER SIZE; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; FEMALE; FIBROCYSTIC BREAST DISEASE; HISTOPATHOLOGY; HUMAN; INFLAMMATION; INTERMETHOD COMPARISON; INTRAVENOUS DRUG ADMINISTRATION; LYMPH NODE METASTASIS; MAMMOGRAPHY; METASTASIS; POSITRON EMISSION TOMOGRAPHY; RADIATION ATTENUATION; SCINTIGRAPHY;

EID: 0030852417     PISSN: 03406997     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF01254246     Document Type: Article

References (45)

1. Kelsey JL, Gammon MD. The epidemiology of breast cancer. Cancer 1991; 41: 146-165.
2. Berg JW, Hutter RV. Breast cancer. Cancer 1995; 75: 257-269.
3. Sondik EJ. Breast cancer trends. Incidence, mortality and survival. Cancer 1994; 74: 995-999.
4. Andersson I. Mammographic screening and mortality from breast cancer: Malmö mammographic screening trial. Br J Med 1988; 297: 943-948.
5. Frisell J, Eklund G, Hellström L, et al. Randomized study of mammography screening - preliminary report on mortality in the Stockholm trial. Breast Cancer Res Treat 1991; 18: 49-56.
6. Miller AB, Baines CJ, To T, et al. Canada national breast screening study. Can Med Assoc J 1992; 147: 1459-1488.
7. Kopans DB. The positive predictive value of mammography. AJR 1992; 158: 521-526.
8. Wahl RL, Cody RL, Hutchins GD, Kuhl DE. Primary and metastatic breast carcinoma: initial clinical evaluation with PET imaging of breast cancer with 18FDG. Radiology 1989; 173: 419.
9. Kubota K, Matsuzawa T, Amemiya A, Kondo M, Fujiwara T, Watanuki S, Ito M, Ido T. Imaging of breast cancer with FDG and positron emission tomography. J Comput Assist Tomogr 1989; 13: 1097-1098.
10. Wahl RL, Cody RL, Hutchins GD, Mudgett EE. Primary and metastatic breast carcinoma: initial clinical evaluation with PET with the radiolabeled glucose analogue F-18 fluoro-2-deoxy-D-glucose. Radiology 1991; 179: 765-770.
11. 18F-deoxyglucose. J Comput Assist Tomogr 1993; 17: 582-589.
12. Tse NY, Hoh CK, Hawkins RH, Zinner MJ, Dahlbom M, Choi Y, Maddahi J, Brunicardi FC, Phelps ME, Glaspy JA. The application of positron emission tomographic imaging with FDG to the evaluation of breast disease. Ann Surg 1992; 216: 27-34.
13. Nieweg OE, Kim EE, Wong WH, Broussard WF, Singletary SE, Hortobagyi GN, Tilbury RS. Positron emission tomography with FDG in the detection and staging of breast cancer. Cancer 1993; 71: 3920-3925.
14. Adler LP, Crowe JP, Al Kaisi NK, Sunshine JL. Evaluation of breast masses and axillary lymph nodes with F-18 deoxy-2-fluoro-D-glucose PET. Radiology 1993; 187: 743-750.
15. Jacobs M, Mantil J, Peterson C, Reiling R, Glaser R, Satter M, Nickerson J, Dunigan K, Brackney M. FDG PET in breast cancer [abstract]. J Nucl Med 1994; 35: 142.
16. Avril N, Jänicke F, Dose J, Bense S, Ziegler S, Zinke M, Laubenbacher C, Römer W, Herz M, Schwaiger M. PET imaging of breast tumors: Munich experience [abstract]. J Nucl Med 1995; 36: 82.
17. Dehdashti F, Mortimer JE, Griffeth LK, McGuire AH, Radford DM, Fusselman MJ, Burney RJ, Bonasera TA, Siegel BA, Katzenellenbogen JA, Welch MJ. Positron tomographic assessment of breast lesions with FDG and FES [abstract]. J Nucl Med 1994; 35: 141.
18. Kao CH, Wang SJ, Liu TJ. The use of technetium-99m methoxyisobutylisonitrile breast scintigraphy to evaluate palpable breast masses. Eur J Nucl Med 1994; 21: 432-436.
19. Khalkhali I, Mena I, Jouanne E, et al. Prone scintimammography in patients with suspicion of breast cancer. J Am Coll Surg 1994; 178: 491-497.
20. Khalkhali I, Cutrone JA, Mena I. Scintimammography: the complementary role of Tc-99m sestamibi prone breast imaging for the diagnosis of breast carcinoma. Radiology 1995; 196: 421-426.
21. Palmedo H, Schomburg A, Gruenwald F, Mallman P, Krebs D, Biersack HJ. Scintimammography with Tc-99m MIBI in suspicious breast lesions. J Nucl Med 1996; 37: 626-630.
22. Taillefer R, Robidoux A, Lambert R, Turpin S, Lamperrière J. Tc-99m sestamibi prone scintimammography to detect primary breast cancer and axillary lymph node involvement. J Nucl Med 1995; 36: 1758-1765.
23. Lee V, Sax EJ, McAneny DB, Pollack S, Blanchard RA, Beazley RM, Kavanah MT, Ward RJ. A complementary role for thallium-201 scintigraphy with mammography in the diagnosis of breast cancer. J Nucl Med 1993; 34: 2095-2100.
24. Waxman AD, Ramanna L, Memsic LD, Foster CE, Silberman AW, Gleischmann SH, Brenner RJ, Brachman MB, Kuhar CJ, Yadegar J. Thallium scintigraphy in the evaluation of mass abnormalities of the breast. J Nucl Med 1993; 34: 18-23.
25. Mansi L, Rambaldi PF, Procaccini E, et al. Scintimammography with Tc-99m tetrofosmin in the diagnosis of breast cancer and lymph node metastases. Eur J Nucl Med 1996; 23: 932-939.
26. Crowe JP, Adler LP, Shenk RR, Sunshine J. Positron emission tomography and breast masses: comparison with clinical, mammographic, and pathological findings. Ann Surg Oncol 1994; 1: 132-140.
27. Khalkhali I, Mena I, Diggles L. Limitations of mammography: the role of Tc-99m sestamibi scintimammography in the diagnosis of breast cancer [abstract]. Clin Nucl Med 1993; 18: 927.
28. Khalkhali I, Cutrone JA, Mena I. Diggles L, Khalkhali S, Venegas R, Klein S. The usefulness of scintimammography (SMM) in patients with dense breasts on mammogram [abstract]. J Nucl Med 1995; 36: 52.
29. Palmedo H, Grünwald F, Bender H, Schomburg A, Mallmann P, Krebs D, Biersack HJ. Scintimammography with technetium-99m methoxyisobutylisonitrile: comparison with mammography and magnetic resonance imaging. Eur J Nucl Med 1996; 23: 940-946.
30. Lannin DR, Harris RP, Swanson FH, Edwards MS, Swanson MS, Pories WJ. Difficulties in diagnosis of carcinoma of the breast in patients less than fifty years of age. Surg Gynecol Obstet 1993; 177: 123-126.
31. Coneney EC, Geraghty JG, O'Laoide R, Hourihane JB, O'Higgins NJ. Reasons underlying negative mammography in patients with palpable breast cancer. Clin Radiol 1994; 49: 123-125.
32. Khalkhali I, Cutrone JA, Mena I, Diggles L, Venegas R, Vargas H, Jackson B, Klein S. Technetium-99m-sestamibi scintimammography of breast lesions: clinical and pathological follow-up. J Nucl Med 1995; 36: 1784-1789.
33. Tilling R, Kress K, Pechmann M, Pfluger T, Knesewitsch P, Tatsch K, Hahn K. Integrated diagnosis of breast tumors: semiquantitative Tc-99m sestamibi imaging versus dynamic MRI [abstract]. J Nucl Med 1995; 35: 51.
34. Diggles L, Mena I, Khalkhali I. Bilateral increased uptake of Tc-99m sestamibi in scintimammography: its correlation with the menstrual cycle [abstract]. J Nucl Med Technol 1994; 22: 111.
35. Wahl RL, Zasadny KR, Cody R, Helvie M. FDG accumulation in normal breasts declines with aging [abstract]. J Nucl Med 1994; 35: 142.
36. Chiu ML, Kronauge JF, Piwnica-Worms D. Effect of mitochondrial and plasma membrane potentials on accumulation of hexakis 2-methoxyisobutylisonitrile technetium in cultured mouse fibroblasts. J Nucl Med 1990; 1646-1653.
37. Maublant JC, Zhang Z, Rapp M, Ollier M, Michelot J, Veyre A. In vitro uptake of technetium-99m teboroxime in carcinoma cell lines and normal cells: comparison with technetium-99m sestamibi and thallium-201. J Nucl Med 1993; 34: 1949-1952.
38. Piwnica-Worms D, Chiu ML, Budding M, Kronauge JF, Kramer RA, Crooop JM. Functional imaging of multidrug-resistant P-glycoprotein with an organotechnetium complex. Cancer Res 1993; 53: 977-984.
39. Bender H, Friedrich E, Zamora PO, Biersack HJ. Detection of multi-drug resistance with Tc-99m sestamibi [abstract]. J Nucl Med 1995; 36 (Suppl) 129P.
40. Ciarmiello A, Del Vecchio S, Potena MI, et al. Technetium-99m-sestamibi efflux and P-glycoprotein expression in human breast carcinoma [abstract]. J Nucl Med 1995; 36 (Suppl) 129P.
41. Maublant J, Songalede JA, Finat-Duclos F, Verrelle P, Veyre A, Younès A. Accumulation of Tc-99m sestamibi in cultured tumor cells decreases when multidrug resistance factor is overexpressed [abstract]. J Nucl Med 1994; 35 (Suppl): 219P.
42. Kubota K, Kubota R, Yamada S. FDG accumulation in tumor tissue. J Nucl Med 1993; 34: 419-421.
43. Hawkins RA, Hoh C, Dahlbom M, et al. PET cancer evaluation with FDG. J Nucl Med 1991; 32: 1555-1558.
44. Weber G. Enzymology of cancer cells. N Engl J Med 1977; 296: 486-493.
45. Avril N, Jänicke F, Dose J, Bense S, Ziegler S, Zinke M, Römer W, Weber W, Herz M, Schwaiger M. PET evaluation of axillary lymph node involvement in breast cancer patients [abstract]. J Nucl Med 1995; 35: 82.